NasdaqCM - Nasdaq Real Time Price USD

Aethlon Medical, Inc. (AEMD)

0.4051

-0.0091

(-2.20%)

As of 1:00:59 PM EDT. Market Open.

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication (https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1) of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin."

PR Newswire 5 hours ago

AEMD
-2.20%
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire last month

GOVX

GOVXW

PLAB
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following con

PR Newswire 2 months ago

AEMD
-2.20%
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire 2 months ago

HGRAF

AEMD
-2.20%

GOSS
Q3 2025 Aethlon Medical Inc Earnings Call

Q3 2025 Aethlon Medical Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

AEMD
-2.20%
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025.

PR Newswire 2 months ago

AEMD
-2.20%
AEMD: Patient Enrollments in Oncology Trial Expected to Accelerate With 3rd Participating Site, Protocol Amendments

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Patient treatments begin in AEMD’s basket oncology trial, enrollments expected to accelerate Aethlon Medical (NASDAQ:AEMD) reported FY 3Q results yesterday and provided a business update. We present our key takeaways in this note: Key takeaways Lead asset the Aethlon Hemopurifier® is being evaluated in combination with checkpoint

Zacks Small Cap Research 2 months ago

AEMD
-2.20%
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments.

PR Newswire 2 months ago

AEMD
-2.20%
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2024, at 4:15 p.m. ET on Wednesday, February 12, 2025.

PR Newswire 3 months ago

AEMD
-2.20%
Aethlon Medical treats first subject with Hemopurifier device in Australia

The treatment with the device lasted four hours and was well-tolerated.

Medical Device Network 3 months ago

AEMD
-2.20%
AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier

By M. Marin NASDAQ:AEMD Aethlon Medical (NASDAQ:AEMD) announced that the first patient in its Australian safety, feasibility and dose-finding clinical trial has been treated with the Hemopurifier. The trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. In other words, the trial is evaluating the Hemopurifier in patients

Zacks Small Cap Research 3 months ago

AEMD
-2.20%
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pe

PR Newswire 3 months ago

AEMD
-2.20%
Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu."

PR Newswire 4 months ago

AEMD
-2.20%
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 5 months ago

BNRG

ICON

VIOT
AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Patient enrollments begin for AEMD’s basket oncology trial Aethlon Medical (NASDAQ:AEMD) announced FY 2Q results and provided a business update yesterday. The company has made significant strides in moving its clinical activities forward over the past few weeks. The company has enrolled the first two patients in its oncology trial

Zacks Small Cap Research 5 months ago

AEMD
-2.20%
Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 14, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.According to a recent article in Bio

Newsfile 5 months ago

AEMD
-2.20%
Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...

Aethlon Medical Inc (AEMD) advances its international oncology trials while managing financial challenges and leveraging tax benefits.

GuruFocus.com 5 months ago

AEMD
-2.20%
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments.

PR Newswire 5 months ago

AEMD
-2.20%
Innovative Medical Technology Advances with First Patient Enrollments

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Read the full article on Investorideas.comhttps://www.invest

Newsfile 5 months ago

AEMD
-2.20%
Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer

The first patient was enrolled at the Cancer Clinical Trials Unit at CALHN, Royal Adelaide Hospital.

Medical Device Network 5 months ago

AEMD
-2.20%

Performance Overview

Return	AEMD	S&P 500 (^GSPC)
YTD	-52.90%	-0.03%
1-Year	-52.34%	+12.07%
3-Year	-96.07%	+46.13%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aethlon Medical, Inc. (AEMD)

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Q3 2025 Aethlon Medical Inc Earnings Call

Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

AEMD: Patient Enrollments in Oncology Trial Expected to Accelerate With 3rd Participating Site, Protocol Amendments

Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

Aethlon Medical treats first subject with Hemopurifier device in Australia

AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier

Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment Measures

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Aethlon Medical Inc (AEMD) Q2 2025 Earnings Call Highlights: Progress in Oncology Trials and ...

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Innovative Medical Technology Advances with First Patient Enrollments

Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer

Performance Overview